Still, the analysts predicted that Ozempic, Wegovy, and Rybelsus (semaglutide) maker Novo Nordisk and Eli Lilly, which developed Zepbound and Mounjaro (tirzepatide), will maintain two-thirds of the market by 2031 due to their first-mover advantages. Other competitors are expected to take a combined $70 billion of the GLP-1 market, the study read
This is the ideal hybrid of hydration and a lip gloss, perfect for when you want
The researchers note that GLP-1 drugs offer protection by reducing harmful brain proteins, inflammation, and insulin resistance
Effects of levothyroxine replacement therapy on parameters of metabolic syndrome and atherosclerosis in hypothyroid patients: a prospective pilot study
Is it safe to have gaps between semaglutide injections
While most GLP-1 drugs are currently available as injections, the introduction of new oral formulations, which could be easier for patients to take, could result in additional shifts in utilization among GLP-1s